Skip to main content
Skip to content
Case File
sd-10-EFTA01462733Dept. of JusticeOther

EFTA Document EFTA01462733

Subject: Re: quick discussion about pharma financing opportunity? [C] From: Paul Morris a> Date: Sat, 16 May 2015 08:40:21 -0400 To: [email protected] Classification: Confidential Will circle back if we move forward Tx From: jeffrey E. [mailto:[email protected]] Sent: Thursday, May 14, 2015 12:21 PM To: Paul Morris Subject: Re: quick discussion about pharma financing opportunity? [C] yes interested On Thu, May 14, 2015 at 12:07 PM, Paul Morris a wrote: Classification: Confi

Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01462733
Pages
3
Persons
0
Integrity
No Hash Available
Loading PDF viewer...

Summary

Subject: Re: quick discussion about pharma financing opportunity? [C] From: Paul Morris a> Date: Sat, 16 May 2015 08:40:21 -0400 To: [email protected] Classification: Confidential Will circle back if we move forward Tx From: jeffrey E. [mailto:[email protected]] Sent: Thursday, May 14, 2015 12:21 PM To: Paul Morris Subject: Re: quick discussion about pharma financing opportunity? [C] yes interested On Thu, May 14, 2015 at 12:07 PM, Paul Morris a wrote: Classification: Confi

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
Subject: Re: quick discussion about pharma financing opportunity? [C] From: Paul Morris a> Date: Sat, 16 May 2015 08:40:21 -0400 To: [email protected] Classification: Confidential Will circle back if we move forward Tx From: jeffrey E. [mailto:[email protected]] Sent: Thursday, May 14, 2015 12:21 PM To: Paul Morris Subject: Re: quick discussion about pharma financing opportunity? [C] yes interested On Thu, May 14, 2015 at 12:07 PM, Paul Morris a wrote: Classification: Confidential jeffrey, we are working on a live situation with a pharma company that is looking to finance the distribution and sales of a newly approved drug. DB is bidding on the debt financing and would need to syndicate out —$50mm to a third party. I expect the transaction to be structured as a royalty arrangement and imagine yields would be in the low double digits. I know you've done equity transactions in biotech area over the years but thought you may have someone interested in a discussion with our structured credit team to see if this would be a fit? Let's catch up soon. Hope all is well, Paul Morris Managing Director Deutsche Bank Private Bank EFTA01462733 Office: Cell: fcid:[email protected] Securities offered through Deutsche Bank Securities Inc. This communication may contain confidential and/or privileged information. If you are not the intended recipient (or have received this communication in error) please notify the sender immediately and destroy this communication. Any unauthorized copying, disclosure or distribution of the material in this communication is strictly forbidden. Deutsche Bank does not render legal or tax advice, and the information contained in this communication should not be regarded as such. please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA01462734 This communication may contain confidential and/or privileged information. If you are not the intended recipient (or have received this communication in error) please notify the sender immediately and destroy this communication. Any unauthorized copying, disclosure or distribution of the material in this communication is strictly forbidden. Deutsche Bank does not render legal or tax advice, and the information contained in this communication should not be regarded as such. EFTA01462735

Technical Artifacts (1)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Link to Specific Page

Share a direct link to a specific page in this document:

https://epsteinexposed.com/documents/sd-10-EFTA01462733?page=[page_number]

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.